COPENHAGEN: The Danish government on Monday, May 31, asked the country’s health authorities to reconsider a decision to exclude COVID-19 vaccines from Johnson & Johnson and AstraZeneca from its vaccination schedule.
The move was prompted by a two-week delay in the Danish vaccination program until September due to the delivery of fewer Moderna and CureVac vaccines than expected, Health Minister Magnus Heunicke said.
Denmark has ruled out the Johnson & Johnson and AstraZeneca vaccines due to a potential link to a rare but serious form of blood clot.
“We are now further into the epidemic, and vaccines from Johnson & Johnson and AstraZeneca have now been in use in Europe for some time,” Heunicke said.
“There is a larger database in the world to assess the effect and side effects of vaccines,” he said.
The health authority discovered in early May that the benefits of using the COVID-19 vaccines did not outweigh the risk of causing the possible side effect in those who receive the vaccine.
The exclusion of the J&J vaccine, which accounts for about a third of Denmark’s total contractual COVID-19 vaccine supplies, has delayed the country’s immunization schedule by up to four weeks, the health authority said.
Denmark had vaccinated 21% of its population on Monday.